Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaxion A/S filings document a foreign private issuer that furnishes Form 6-K reports for business updates, financial results, clinical and preclinical vaccine-program disclosures, and governance actions. Recent reports describe AI-Immunology™-powered vaccine development, EVX-01 personalized cancer vaccine data in advanced melanoma, platform work in glioblastoma, and infectious disease vaccine design concepts.
The filing record also includes annual general meeting results, approval of the audited annual report, board and auditor elections, leadership-role disclosures, and incorporation of Form 6-K reports by reference into Form S-8, Form F-1, and Form F-3 registration statements. These documents frame Evaxion’s capital-market disclosures around pipeline development, corporate governance, securities registrations, and recurring operating updates.
Evaxion A/S states that it will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma at the ESMO Congress 2026 in Madrid. The third-year extension includes EVX-01 as stand-alone therapy without anti-PD-1 combination.
The company highlights previously reported two-year results in 16 patients: an Objective Response Rate of 75% with 12 objective responses and 4 complete responses; 92% of patients were still responding at two years with no relapses, tumor reduction in 15 patients, and EVX-01–induced immune responses in all patients, with 86% of targeted neoantigens generating potent T-cell responses.
Evaxion A/S reports new preclinical data for its cytomegalovirus (CMV) vaccine program EVX‑V1, developed using its AI‑Immunology™ platform. The data, presented in a poster at the International Herpesvirus Workshop 2026 in Montreal, show that novel AI‑discovered T‑cell epitopes may improve control of acute CMV infection, latency and viral reactivation in CMV‑infected mice.
These findings complement earlier preclinical results where novel B‑cell antigens reduced viral infection and optimized structural B‑cell antigens mediated superior viral neutralization. EVX‑V1 combines these novel antigens with an AI‑optimized pre‑fusion glycoprotein B (gB) antigen, aiming for a broader, multi‑targeted immune response and a potentially more protective CMV vaccine concept that could extend to other herpesviruses.
Evaxion A/S reports it will present new preclinical data for its cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal. The poster on July 12, 2026 will highlight AI-driven multi-antigen vaccine design to address CMV infection, latency and immune evasion.
EVX-V1 combines novel AI-discovered CMV antigens with AI-optimized versions of established antigens, aiming for a broadly protective, multi-targeted vaccine approach. The new data are intended to guide final antigen selection as the program progresses. The filing also describes CMV’s high global prevalence and significant unmet medical need.
Evaxion A/S, a clinical-stage TechBio company, reports that its AI-Immunology™ platform has received the 2026 Prix Galien UK Award for Best digital health solution. The prize recognizes the platform’s use of artificial intelligence to decode the human immune system and generate novel vaccine candidates for cancer and infectious diseases.
This is Evaxion’s second recognition from the Galien Prix Foundation in less than a year, following a December 2025 award for Best Medical Technology / AI Advances in Nordic and high-growth regions. The UK award was decided by a committee of 12 scientific leaders, who evaluated innovation, clinical application, scientific insights and impact on human health.
Evaxion A/S reports new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia (AML), developed with its AI-Immunology™ platform. The data show EVX-04 is fully expressed and secreted in human cells, enabling immune recognition and activation.
All endogenous retrovirus antigens included in EVX-04 trigger specific immune responses in mice and human cells with different immune profiles, leading to targeted cell-killing and prevention of tumor growth in preclinical models. The results will be presented in a poster at the European Hematology Association 2026 Congress, and Evaxion is preparing a regulatory filing for clinical testing.
Evaxion A/S is highlighting progress on its EVX-04 cancer vaccine program by presenting new preclinical data at the EHA 2026 Congress. The poster on June 13, 2026 will cover the functional characterization of EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia.
Developed using Evaxion’s AI-Immunology™ platform, EVX-04 targets endogenous retrovirus tumor antigens that are present in AML tumors but not in normal tissue. In preclinical models, all 16 antigen fragments in EVX-04 trigger specific immune responses and prevent tumor growth, supporting its potential as a broadly applicable off-the-shelf vaccine.
The company states that these data are another step toward clinical testing and that it plans to submit a clinical trial application for EVX-04 in the second half of 2026. Background in the report underscores the high unmet need in AML, where survival rates remain low despite intensive and low-intensity chemotherapy options.
Evaxion A/S reported first quarter 2026 results alongside a broad business update. The company remains focused on its AI-Immunology™ platform, which showed 86% vaccine target recognition in its personalized cancer vaccine EVX-01, reinforcing the platform’s ability to trigger tumor-specific immune responses.
Evaxion completed a one-year extension of its phase 2 EVX-01 melanoma trial and plans to present three-year data in the second half of 2026. It also presented new polio vaccine design concepts from its collaboration with The Gates Foundation and data supporting AI-Immunology™ use in glioblastoma.
For the quarter, Evaxion recorded a net loss of $3.6 million, compared with $1.6 million a year earlier, mainly due to lower finance income. Cash and cash equivalents were $18.4 million as of March 31, 2026, supporting a cash runway into the second half of 2027.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines for cancer and infectious diseases, has scheduled a business update and its first quarter 2026 financial results release for May 7, 2026 before the opening of the Nasdaq CM.
The company’s executive management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Registration is required to receive dial-in details and a unique PIN, and a webcast recording will be available on Evaxion’s website afterward.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has promoted Chief Scientific Officer Birgitte Rønø to a dual role as Chief Scientific and Chief Operating Officer. This change follows an internal management review aimed at aligning the organization to better execute its strategy and increase external visibility of its AI-Immunology™ platform with partners and investors.
The promotion recognizes Dr. Rønø’s long-standing contribution to Evaxion’s internal operations and scientific leadership. Following the change, the management team consists of CEO Helen Tayton-Martin, CSO and COO Birgitte Rønø, CFO Thomas Schmidt, and Chief AI Officer Andreas Mattsson. The filing also reiterates Evaxion’s focus on AI-driven vaccine candidates for cancer and infectious diseases.
Evaxion A/S director Jens Bitsch-Norhave filed an initial Form 3 reporting indirect ownership of 2,376 Ordinary Shares. The shares are held through Sprout Invest Aps, an entity owned 50% by Mr. Bitsch-Norhave and 50% by his spouse. The filing does not report any new buy or sell transactions.